Treace Medical Concepts, INC 10-Q quarterly reports

Treace Medical Concepts reported a 4.2% revenue decrease in Q2 2026 compared to the prior year, alongside an increased net loss and ongoing litigation.

Treace Medical Concepts reported a 10.2% revenue decrease in Q1 2026 compared to the prior year, driven by a shift from higher-priced Lapiplasty systems to lower-priced minimally invasive alternatives.

Treace Medical Concepts reports an 11.4% revenue increase in Q3 2025, driven by new product sales and initial stocking orders, but faces increased net losses due to rising legal and operating expenses.

Treace Medical Concepts reported a narrower net loss and increased revenue for the second quarter and first half of 2025, driven by higher product sales and reduced sales and marketing expenses.

Treace Medical Concepts saw a slight increase in revenue for the first quarter of 2025, while continuing to invest in new product development and manage macroeconomic headwinds.

Treace Medical Concepts saw a 10.6% increase in revenue in the third quarter of 2024 compared to the same period last year, driven by new product adoption and increased sales of ancillary products.

Treace Medical Concepts experienced a revenue increase of 6% year-over-year in the second quarter, but also saw a significant rise in operating expenses and net losses.

Treace Medical Concepts saw a 21.1% increase in revenue in the first quarter of 2024 compared to the same period last year, driven by higher sales volumes and a shift towards newer products.